Invention Grant
- Patent Title: Recombinant rabies virus compositions
- Patent Title (中): 重组狂犬病病毒组合物
-
Application No.: US11571842Application Date: 2005-07-12
-
Publication No.: US07695724B2Publication Date: 2010-04-13
- Inventor: Bernhard Dietzschold , Marie Luise Faber , Matthias Schnell , Milosz Faber
- Applicant: Bernhard Dietzschold , Marie Luise Faber , Matthias Schnell , Milosz Faber
- Applicant Address: US PA Philadelphia
- Assignee: Thomas Jefferson University
- Current Assignee: Thomas Jefferson University
- Current Assignee Address: US PA Philadelphia
- Agency: Brinker Biddle & Reath LLP
- Agent Daniel A. Monaco
- International Application: PCT/US2005/024671 WO 20050712
- International Announcement: WO2006/017276 WO 20060216
- Main IPC: A61K39/205
- IPC: A61K39/205 ; C12N7/00 ; C12N7/01 ; C12N15/86

Abstract:
Recombinant rabies viruses in which the arginine residue of the glycoprotein (G) at amino acid position 333 is exchanged, renders these viruses nonpathogenic for immunocompetent mammals regardless of the route of infection. Some of these recombinant rabies viruses after several serial virus passages in newborn mice can become pathogenic for adult mice. The reversion to the pathogenic phenotype is associated with a thymidine to adenosine mutation (T→A) at position 639 of the G gene, which results in an asparagine to lysine exchange at position 194 of G. The codon at position 637-639 was changed by site directed mutagenesis to replace asparagine at position 194 by an amino acid that minimized the possibility for an Asn→Lys exchange at amino acid position 194 of G and prevents reversion to a pathogenic form of the virus.
Public/Granted literature
- US20080003657A1 Recombinant Rabies Virus Compositions Public/Granted day:2008-01-03
Information query